“Differential Impact of HLA-A, -B, and -DRB1 Mismatching in Relation to Other Variables on the Outcomes of Myeloablative Unrelated Single Donor Umbilical Cord Blood Transplantation From 4/6 Matched Units in Children and Young Adults”, presented at the 2011, Honolulu, HI, 2011, vol. 17 No 2 Su, pp. S 185 - 186.
, “Differential Effects of Antiepileptic Drugs on Neonatal Outcomes”, Epilepsy Behav, vol. 24, pp. 449-456, 2012.
, “Reticular Drusen as a Baseline Risk Factor for Progression to Advanced AMD in AREDS”, presented at the 01/05/2005, Fort Lauderdale, FL, 2005.
, “Risk Factors Associated With Incident Cataracts and Cataract Surgery in the Age-Related Eye Disease Study (AREDS): AREDS Report Number 32”, Opthalmology, vol. 118, pp. 2113-2119, 2011.
, “Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120,”, Ann Intern Med, vol. 125, p. 270, 1996.
, , “Characteristics Associated With Severe Perineal and Cervical Lacerations During Vaginal Delivery”, Obstet Gynecol, vol. 117, pp. 627-635, 2011.
, “Clinical trials referral resource. Clinical trials in elderly patients.”, Oncology, vol. 11, pp. 838-44, 1997.
, “Lessons from IAVI-006, a Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the PTHR.HIVA DNA and MVA.HIVA Vaccines in a Prime-Boost Strategy to Induce HIV-1 Specific T-Cell Responses in Healthy Volunteers”, Vaccine, vol. 26, pp. 6671-6677, 2008.
, “Clinical trials referral resource. Clinical trials with PSC-833”, Oncology, vol. 11, pp. 490-3, 1997.
, “Retrospective Studies: A Fresh Look.”, Am J Speech Lang Pathol, vol. 25, no. 2, pp. 157-63, 2016.
, “Evaluation of the Mercy TAPE: Performance Against the Standard for Pediatric Weight”, Ann Emerg Med, vol. 62, pp. 332-339.e6, 2013.
, “Evaluation of the Mercy TAPE: performance against the standard for pediatric weight estimation.”, Ann Emerg Med, vol. 62, no. 4, pp. 332-339.e6, 2013.
, “Validation and human factor analysis study of an infant weight estimation device.”, BMC Pediatr, vol. 20, no. 1, p. 30, 2020.
, “Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study”, in 62nd ASH Annual Meeting and Exposition, 2020.
, “Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study”, in American Society of Hematology (ASH), 2020.
, “Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study”, Blood Adv, vol. 7, no. 14, pp. 3506-3515, 2023.
, “Meeting highlights: a reappraisal of research results for the local treatment of early stage breast cancer.”, J Natl Cancer Inst, vol. 87, no. 24, pp. 1837-45, 1995.
, “Clinical trials referral resource. Current cooperative group phase III clinical trials in early-stage breast cancer.”, Oncology (Williston Park), vol. 15, no. 2, pp. 176-7, 181-2, 185, 2001.
, “Clinical trials referral resource. Current phase III, NCI-supported, Cooperative Group Clinical Trials in breast cancer.”, Oncology (Williston Park), vol. 18, no. 4, pp. 463-4, 467-8, 470, 2004.
, “Current Cooperative Group phase III clinical trials in early stage breast cancer”, Oncology, vol. 15, pp. 52-56, 2001.
, “Paclitaxel Activity in Heavily Pretreated Breast Cancer: A National Cancer Institute Treatment Referral Center Trial”, J Clin Oncol, vol. 13, pp. 2056-2065, 1995.
, “Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.”, J Clin Oncol, vol. 13, no. 8, pp. 2056-65, 1995.
, “Meeting Highlights: A Reappraisal of Research Results For the Local Treatment of Early Stage Breast Cancer”, J Natl Cancer Inst, vol. 87, pp. 1837-1845, 1995.
, ,